Propel Bio Management LLC Invests $434,000 in Compass Therapeutics, Inc. $CMPX

Key Points

• Propel Bio Management LLC has acquired a new position in Compass Therapeutics, purchasing 228,317 shares valued at approximately $434,000.
• Compass Therapeutics has received new price targets from analysts, with D. Boral Capital setting a target of $32.00 and Guggenheim increasing their target to $12.00.
• The stock has shown significant price movement, opening at $3.49 with a 1-year low of $1.25 and a high of $4.08, and presently holds an average rating of "Buy" among analysts.

Propel Bio Management LLC purchased a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 228,317 shares of the company's stock, valued at approximately $434,000. Compass Therapeutics makes up 0.5% of Propel Bio Management LLC's holdings, making the stock its 15th biggest holding. Propel Bio Management LLC owned about 0.17% of Compass Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Walleye Trading LLC bought a new position in shares of Compass Therapeutics in the 1st quarter valued at $48,000. Walleye Capital LLC acquired a new stake in Compass Therapeutics in the first quarter worth $100,000. Wellington Management Group LLP bought a new position in Compass Therapeutics in the first quarter worth approximately $423,000. American Century Companies Inc. acquired a new stake in shares of Compass Therapeutics in the 1st quarter worth about $140,000. Finally, Nuveen LLC bought a new stake in Compass Therapeutics during the first quarter worth $579,000. 68.43% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, August 12th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a research report on Tuesday, July 1st. Finally, Guggenheim upped their target price on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $12.89.

Compass Therapeutics Stock Down 1.7%

Compass Therapeutics stock traded down $0.06 during midday trading on Wednesday, reaching $3.37. 322,999 shares of the company traded hands, compared to its average volume of 1,425,707. Compass Therapeutics, Inc. has a 12 month low of $1.27 and a 12 month high of $4.08. The business has a 50 day moving average of $2.97 and a two-hundred day moving average of $2.47.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Research analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.